Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think we're in store a breakout next week. Been showing some nice strength with a 12% rise in price the past 2 days combined. Expecting the real breakout to come next week from a break of .53-.54
WORLD VACCINE CONGRESS 2009
Congress Day 3: Thursday 8 October 2009
http://www.terrapinn.com/2009/wvcl/programme.stm
11.40
How outsourcing can enhance and speed up development towards licensure of vaccines
Dr Hanna Nohynek, Senior Vaccine Consultant,
Encorium
12.10
Panel session: how can you align strategies with regulation to avoid barriers to vaccine development?
Ms Mary Allin, Senior Director, Regulatory Affairs,
Wyeth Research
Stephen Cook, Vice President, Head of Worldwide Vaccine Registration Management,
GlaxoSmithKline Biologicals
Dr Hanna Nohynek, Senior Vaccine Consultant,
Encorium
I'm loving the technical setup of this stock. It has a bounce off the 50 RSI forming and a bounce of 20 on stochastics forming as well. These are both very bullish and should indicate a strong reversal. This looks like a good entry and a break of around .53 should indicate a major breakout.
An older Report that has Encorium in it: Global CRO Market 2005- $15 Billion
http://www.cipher-sys.com/Global%20Contract%20Research%20Organizations.pdf
What is causing todays run? Is there more after hours news coming? Seems that is how they like to put out news! Something for sure is up!
...old one - listed at IBOX!
caused not todays run...
H1N1 (ENCO) Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win; Company Successful with its Strategic Focus on Vaccines and Oncology Trials 9/9/2009
WHAT THE HELL IS HAPPENING! BUYOUT??? PARTNERSHIP???? THIS IS SCREAMING BACK TO A BUCK!!
Swine Flu vaccine approved by FDA. Now lets rock already!
Sure does! With the O/S almost trading twice above the current PPS in the last few days, it makes you wonder. Most pops will have some correction, but when they bounce, they rebound quick. IMO Look at HYTM... Just bounced for almost 100% after a nice pop...:) There are a few MA crosses on the way, so watch out:
Over 40m shares have traded in the last 3 days with a 11.7m float. Wow! Per Yahoo:
A/S: 35,000,000
O/S: 25,520,000
FLOAt: 11,720,000
Are you kidding me? The float has traded almost 4 times??! What gives!?
ENCO - weekly
Key Statistics 'ENCO'
http://finance.yahoo.com/q/ks?s=enco
ENCO - @ Barchart.com
http://quote.barchart.com/texpert.asp?sym=enco&code=BSTK
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 2294840
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 967368
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell
Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 520570
Overall Average: 80% - Buy
Price Support Pivot Point Resistance
0.70 0.59 0.71 0.83
Encorium Group Inc. -
http://www.shortsqueeze.com/?symbol=enco&submit=Short+Quote%99
Shares Float 11,720,000
Total Shares Outstanding 20,523,883
% Owned by Insiders 42.00 %
% Owned by Institutions 24.60 %
Record Date 2009-SepA
Today news>Statement of Ownership (SC 13G)
Date : 09/10/2009 @ 11:19AM
Source : Edgar (US Regulatory)
Stock : (ENCO)
Quote : 0.74 0.03 (4.23%) @ 7:22AM
- Statement of Ownership (SC 13G)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Encorium Group, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
29257R109
(CUSIP Number)
September 10th, 2009
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
þ Rule 13d-1(c)
o Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
--------------------------------------------------------------------------------
CUSIP No.
29257R109
1 NAMES OF REPORTING PERSONS
Ilari Koskelo
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
(b) o
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
5 SOLE VOTING POWER
NUMBER OF 1,430,177
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 1,430,177
WITH: 8 SHARED DISPOSITIVE POWER
0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,430,177
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
o
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.968%
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
--------------------------------------------------------------------------------
Item 1.
(a) Name of Issuer
Encorium Group, Inc.
(b) Address of Issuer’s Principal Executive Offices
One Glenhardie Corporate Center, 1275 Drummers Lane, Suite 100, Wayne, PA 19087
Item 2.
(a) Name of Person Filing
Ilari Koskelo
(b) Address of Principal Business Office or, if none, Residence
c/o Navdata OY, Eskolantie 1, 00720 Helsinki, Finland
(c) Citizenship
Finland
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
29257R109
Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c)
(b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
(e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
(f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
(g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
(h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
--------------------------------------------------------------------------------
(j) o Group, in accordance with 240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: 1,430,177
(b) Percent of class: 6.968%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 1,430,177
(ii) Shared power to vote or to direct the vote 0
(iii) Sole power to dispose or to direct the disposition of 1,430,177
(iv) Shared power to dispose or to direct the disposition of 0
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.
o .
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
--------------------------------------------------------------------------------
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
September 10th, 2009
Date
s/s ilari koskelo
Signature
Ilari Koskelo
Name/Title
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
<< Back
Bookmark With :
Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial W
Date : 09/09/2009 @ 8:30AM
Source : PR Newswire
Stock : (ENCO)
Quote : 0.7486 0.0386 (5.44%) @ 7:22AM
Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial W
Company Successful with its Strategic Focus on Vaccines and Oncology Trials
BERWYN, Pa., Sept. 9 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (NASDAQ:ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced the signing of approximately $8.7 million of new business contracts, including selection by a major pharmaceutical company for participation in a swine flu vaccine program.
Dr. Kai Lindevall, executive chairman stated, "We are delighted to be able to announce these new business awards, despite a very challenging market environment. Our experience and capabilities in the vaccine field have been of paramount importance in our success. We are very proud of being the selected partner for one of the frontline clinical development programs for the swine flu vaccine. In addition, we were also recently entrusted with a avian flue vaccine, as well as other vaccine development programs having, in the aggregate, approximately 12,000 patient subjects. We believe our participation in these studies exemplifies the level of trust and respect that large vaccine companies have in our vaccine expertise and clinical operations.
"We believe Encorium has developed into one of the strongest medium sized clinical research organizations with expertise in the field of clinical vaccine development. Our recent success in the vaccine field has been substantial, with revenues from vaccine trials increasing by 150% in 2009 versus 2008. As an acknowledgement of our achievements, in April 2009, Encorium was nominated as a finalist for the Second Annual Vaccine Industry Excellence Award.
"The establishment of our Core Vaccine Team has made it possible to enter strategic partnerships with a number of clients. Moving forward, our goal is to grow into the world's leading vaccine franchise and to create a vertical niche expertise in the field of vaccine research, covering pre-clinical support, regulatory consultancy and strategic trial planning. As an integral part of this strategy, the Company has began and plans to continue creating global investigator and clinic networks to strengthen the Company's ability to conduct large scale global phase III vaccine trials. Through these networks it will be possible for us to achieve fast and efficient subject/patient recruitment for vaccine trials globally, which will also ensure a strong local ownership and a strong ethical foundation.
"The Company has also been successful in winning trials in the field of oncology during 2009. Thus far in 2009, Oncology trials constitute the second largest revenue generating therapeutic field after vaccines. We believe our vaccine experience will continue to assist us in gaining new contract wins in the oncology sector, as we will continue to focus, not just on prophylactic vaccines, but also on therapeutic vaccines, which constitute a substantial number of oncology trials and are the fastest growing area within vaccine development. Based on our expertise and success in the field of vaccines and oncology, we believe we are well positioned to further strengthen our market position in these niche areas."
The new business awards announced today mitigate any negative impact to our backlog as reported at June 30, 2009 from foreign currency translations, contract amendments and terminations and revenue recognized. The Company had reported consolidated backlog at June 30, 2009 from continuing operations of $19.6 million which compared to a backlog of $23.5 million at June 30, 2008.
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.
This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii)our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; and (xiii) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2009 for a more complete discussion of factors which could cause our actual results and financial position to change.
DATASOURCE: Encorium Group, Inc.
CONTACT: Encorium Group, Inc., Philip L. Calamia, Chief Financial
Officer, +1-610-975-9533, http://www.encorium.com/
Web Site: http://www.encorium.com/
<< Back
Bookmark With :
Historical Chart Intraday Chart
Period
1 month 2 months 3 months 6 months 1 year 2 years 3 years 5 years
Line Line (Square) Candlesticks Bars
Any opinions on what's in store for this one. Is she going to keep running or fall?
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
131
|
Created
|
09/09/09
|
Type
|
Free
|
Moderators |
Encorium Group, Inc. designs and manages clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe.
The company's clinical research and development services supporting Phase I through Phase IV clinical trials include data management, such as CRF review and tracking, data entry, clinical/statistical reports, and writing manuscripts for publication; and biostatistics for the use of professionals to develop and review protocols, design analysis plans, and report formats in various phases of drug development.
Its services also include strategic trial planning; project management; medical writing; quality assurance and compliance, such as investigator audits, pre-submission protocol compliance audits, and GCP audits; outsourcing clinical staff; and clinical trials management comprising case report form design, investigator recruitment, patient enrollment, and study monitoring and data collection.
In addition, Encorium's services include study protocol design; medical and regulatory affairs, such as regulatory strategy formulation, new drug and biologic license application document preparation and review, and quality assurance and liaison; pharmacovigilance; compliance and medical report writing; patient registries; and medical device certification.
It also licenses Oracle Clinical and Datafax as its clinical trials management systems.
Encorium offers clinical trial services in various therapeutic areas, such as cardiovascular, nephrology, endocrinology/metabolism, hematology, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, rheumatology, urology, ophthalmology, women's health, and respiratory medicine.
It was formerly known as Covalent Group, Inc. and changed its name to Encorium Group, Inc. in October 2006 in connection with the acquisition of Remedium Oy. The company was founded in 1989 and is headquartered in Wayne, Pennsylvania.
610-989-4208
(Registrant’s telephone number, including area code)
One Glenhardie Corporate Center, 1275 Drummers Lane,
Suite 300, Wayne, Pennsylvania
Headlines I
14-Jan-10 08:30AM Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
16-Feb-10 04:45PM Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split
Do your own DD & trade smart
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |